Regulatory Approval Process Sample Clauses

Regulatory Approval Process. Mirant, Buyers, the Stockholder and del Caribe shall, as promptly as practicable but in no event later than thirty (30) days following the execution and delivery of this Agreement, submit to the appropriate agencies or third parties all consent requests, declarations, filings and registrations listed on Schedules 2.7, 2.8 and 3.4. With respect to any filings that may be required to be submitted to FERC, Mirant, Buyers, the Stockholder and del Caribe shall cooperate to share and develop information necessary for such filings and drafts of such filings within fifteen (15) days following execution and delivery of this Agreement, and shall give each other reasonable opportunity to comment on and to revise such draft filings before such filings are submitted to FERC.
Regulatory Approval Process. The Parties acknowledge and agree that it is essential that the Closing occur prior to December 31, 1999, and that the Seller may suffer certain adverse consequences if the Closing does not take place by that time. Accordingly, the Buyer hereby covenants that it shall (x) submit its portion of the draft applications, including all required exhibits and attachments, under Sections 203 and 205 of the Federal Power Act substantially in a form ready for filing with the FERC (the "FERC Applications") to the Seller on or before August 2, 1999 for the Seller's review and (y) cooperate with the Seller with a view to filing the FERC Applications with the FERC in accordance with the rules and regulations of the FERC on or before August 17, 1999 and shall not thereafter seek to amend or withdraw such FERC Applications.
Regulatory Approval Process. Where required, the Recipient shall seek approval from the applicable regulatory authority and/or oversight body to implement the dynamic pricing with randomization project. If the Recipient receives approval from the applicable regulatory body and/or oversight board for the dynamic pricing with randomization project consistent with what is specified in the approved Consumer Behavior Study Plan, the study may proceed under current funding levels.
Regulatory Approval Process. The building permit processes, ROW management and similar regulatory requirements that apply to WANRack’s Facilities are completely separate from the requirements of this Agreement. WANRack’s satisfaction of any requirement of this Agreement does not count toward any compliance with any regulatory requirement. WANRack’s satisfaction of any regulatory requirement does not count toward compliance with any requirement of this Agreement. WANRack must make all submittals and communications regarding the requirements of this Agreement through the City’s contract administrator for this Agreement, and not through planning, building safety or other staff. WANRack must obtain all approvals in accordance with all present and future City codes, policies and procedures.
Regulatory Approval Process. 12.1 CN will pursue the process of approval for the import or manufacture of the product in the Territories at CN’s sole expense.
Regulatory Approval Process. Where required, the Recipient shall seek approval from the applicable regulatory authority and/or oversight body to implement the dynamic pricing with randomization project. If the Recipient receives approval from the applicable regulatory body and/or oversight board for the dynamic pricing with randomization project consistent with what is specified in the approved Consumer Behavior Study Plan, the study may proceed under current funding levels. For Official Use Only 30 The Recipient and the Department of Energy (DOE) understand that the Recipient’s project scope, budget and project execution plan are based on the assumption that the Smart Grid Investment Grant (SGIG) funds provided by DOE will be considered nontaxable income under Internal Revenue Code (IRC) 118(a). As of the date of this Agreement, the Internal Revenue Service (“IRS”) has not yet issued guidance or otherwise made a determination regarding the applicability of IRC 118(a) under the SGIG program. For this reason and so that the Recipient is not prejudiced by an IRS determination following the execution of this Agreement, the process set out below will be followed in the circumstances described:
Regulatory Approval Process. Buyer and the Sellers shall, as promptly as practical, but in no event later than thirty days following the execution and delivery of this

Related to Regulatory Approval Process

Regulatory Approval 23.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.
Regulatory Approvals All Consents of, filings and registrations with, and notifications to, all Regulatory Authorities required for consummation of the Merger shall have been obtained or made and shall be in full force and effect and all waiting periods required by Law shall have expired. No Consent obtained from any Regulatory Authority which is necessary to consummate the transactions contemplated hereby shall be conditioned or restricted in a manner (including requirements relating to the raising of additional capital or the disposition of Assets) which in the reasonable judgment of the Board of Directors of either Party would so materially adversely impact the economic or business benefits of the transactions contemplated by this Agreement that, had such condition or requirement been known, such Party would not, in its reasonable judgment, have entered into this Agreement.
Approval Process Landlord shall notify Tenant whether it approves of the submitted working drawings within ten business days after Tenant’s submission thereof. If Landlord disapproves of such working drawings, then Landlord shall notify Tenant thereof specifying in reasonable detail the reasons for such disapproval, in which case Tenant shall, within five business days after such notice, revise such working drawings in accordance with Landlord’s objections and submit the revised working drawings to Landlord for its review and approval. Landlord shall notify Tenant in writing whether it approves of the resubmitted working drawings within five business days after its receipt thereof. This process shall be repeated until the working drawings have been finally approved by Tenant and Landlord.
Required Regulatory Approvals All authorizations, consents, orders and approvals of, and declarations and filings with, and all expirations of waiting periods imposed by, any Governmental Entity (other than the FCC or the appropriate Governmental Entity under the HSR Act) which, if not obtained in connection with the consummation of the transactions contemplated hereby, could reasonably be expected to have a Material Adverse Effect on the Parent or Company (collectively, "Company Required Regulatory Approvals"), shall have been obtained, have been declared or filed or have occurred, as the case may be, and all such Company Required Regulatory Approvals shall be in full force and effect and shall not have any term, condition or restriction unacceptable to Parent in its sole discretion (except as provided in Section 4.2).
Regulatory Applications (a) Summit and GAFC and their respective Subsidiaries shall cooperate and use their respective reasonable best efforts to prepare all documentation, to effect all filings and to obtain all permits, consents, approvals and authorizations of all third parties and Governmental Authorities necessary to consummate the transactions contemplated by this Agreement. Each of Summit and GAFC shall have the right to review in advance, and to the extent practicable each will consult with the other, in each case subject to applicable laws relating to the exchange of information, with respect to, all material written information submitted to any third party or any Governmental Authority in connection with the transactions contemplated by this Agreement. In exercising the foregoing right, each of the parties hereto agrees to act reasonably and as promptly as practicable. Each party hereto agrees that it will consult with the other party hereto with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and Governmental Authorities necessary or advisable to consummate the transactions contemplated by this Agreement and each party will keep the other party apprised of the status of material matters relating to completion of the transactions contemplated hereby.
No Regulatory Approval By the Company or Parent, if its Board of Directors so determines by a vote of a majority of the members of its entire Board, in the event any Requisite Regulatory Approval shall have been denied by final, nonappealable action by such Governmental Authority or a Governmental Authority shall have requested the permanent withdrawal of an application therefor.
Other Regulatory Approvals All necessary approvals, authorizations and consents of any governmental or regulatory entity required to consummate the Merger shall have been obtained and remain in full force and effect, and all waiting periods relating to such approvals, authorizations and consents shall have expired or been terminated.
Clinical Studies The preclinical studies and tests and clinical trials described in the Registration Statement, the Time of Sale Prospectus and the Prospectus were, and, if still pending, are being conducted in all material respects in accordance with the experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company; the descriptions of such studies, tests and trials, and the results thereof, contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus are accurate and complete in all material respects; the Company is not aware of any tests, studies or trials not described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the results of which reasonably call into question the results of the tests, studies and trials described in the Registration Statement, the Time of Sale Prospectus and the Prospectus; and the Company has not received any written notice or correspondence from the FDA or any foreign, state or local Governmental Authority exercising comparable authority or any institutional review board or comparable authority requiring the termination, suspension, clinical hold or material modification of any tests, studies or trials.